PMID- 38043360
OWN - NLM
STAT- MEDLINE
DCOM- 20240116
LR  - 20240116
IS  - 1532-2157 (Electronic)
IS  - 0748-7983 (Linking)
VI  - 50
IP  - 1
DP  - 2024 Jan
TI  - Value of routine follow-up for recurrence detection after treatment with curative 
      intent for laryngeal squamous cell carcinoma.
PG  - 107304
LID - S0748-7983(23)00942-3 [pii]
LID - 10.1016/j.ejso.2023.107304 [doi]
AB  - INTRODUCTION: The benefits of routine follow-up after treatment of primary 
      laryngeal squamous cell carcinoma (LSCC) remain disputed. Guidelines worldwide 
      are consensus-based, and evidence for specific subgroups is lacking. This study 
      evaluates routine LSCC follow-up including flexible endoscopy for detecting 
      locoregional recurrence (LRR). METHODS: A retrospective cohort of 413 LSCC 
      patients treated between 2006 and 2012 was analysed. The cumulative risk of LRR 
      was calculated. Routine follow-up was evaluated by follow-up visit (routine or 
      interval) at which LRR was detected, LRR treatment intent, and overall survival 
      (OS). Analyses were stratified by early (I-II) and advanced (III-IV) TNM-stage. 
      RESULTS: There were 263 (64 %) patients with early-stage and 132 (32 %) patients 
      with advanced-stage LSCC. One-, two- and five-year cumulative risks for LRR after 
      early-stage LSCC were 8 %, 18 %, and 26 %. For advanced-stage LSCC, cumulative 
      risks of LRR were 20 %, 30 %, and 35 %. Of all 69 LRRs after early-stage LSCC, 
      72 % were routine-detected, 81 % were symptomatic, and 90 % received 
      curative-intent treatment. Of all 45 LRRs following advanced-stage LSCC, 42 % 
      were routine-detected, 84 % were symptomatic, and 62 % received curative-intent 
      treatment. Five-year OS of early-stage LSCC with routine-detected LRR was 70 %, 
      and 72 % for interval-detection (log-rank-p = 0.91). Five-year OS of 
      advanced-stage LSCC with routine-detected LRR was 37 %, and 18 % for 
      interval-detection (log-rank-p = 0.06). CONCLUSIONS: Routine follow-up for 
      detecting asymptomatic recurrences seems redundant for early-stage LSCC. After 
      advanced-stage LSCC, no asymptomatic recurrences were detected beyond one year 
      posttreatment despite regular follow-up. Emphasis should be on other follow-up 
      aspects, such as psychosocial support, especially after one year posttreatment.
CI  - (c) 2023 Published by Elsevier Ltd.
FAU - van de Weerd, Cecile
AU  - van de Weerd C
AD  - Radboud University Medical Center, Department of Otorhinolaryngology and Head and 
      Neck Surgery, Nijmegen, the Netherlands. Electronic address: 
      Cecile.vandeweerd@Radboudumc.nl.
FAU - Geurts, Sandra M E
AU  - Geurts SME
AD  - Maastricht University Medical Center, Department of Medical Oncology, GROW School 
      for Oncology and Reproduction, Maastricht, the Netherlands.
FAU - Vercoulen, Richard J M T
AU  - Vercoulen RJMT
AD  - Radboud University Medical Center, Department of Otorhinolaryngology and Head and 
      Neck Surgery, Nijmegen, the Netherlands.
FAU - van Veggel, Inge H F
AU  - van Veggel IHF
AD  - Radboud University Medical Center, Department of Otorhinolaryngology and Head and 
      Neck Surgery, Nijmegen, the Netherlands.
FAU - Brands, Maria T
AU  - Brands MT
AD  - Hospital Network Antwerp, Middelheim Medical Center, Department of Oral and 
      Maxillofacial Surgery, Antwerp, Belgium.
FAU - Marres, Henri A M
AU  - Marres HAM
AD  - Radboud University Medical Center, Department of Otorhinolaryngology and Head and 
      Neck Surgery, Nijmegen, the Netherlands.
FAU - Hermens, Rosella P M G
AU  - Hermens RPMG
AD  - Radboud University Medical Center, Department of IQ Healthcare, Nijmegen, the 
      Netherlands.
FAU - van Tol-Geerdink, Julia J
AU  - van Tol-Geerdink JJ
AD  - Radboud University Medical Center, Department of Radiation Oncology, Nijmegen, 
      the Netherlands.
FAU - Kaanders, Johannes H A M
AU  - Kaanders JHAM
AD  - Radboud University Medical Center, Department of Radiation Oncology, Nijmegen, 
      the Netherlands.
FAU - Takes, Robert P
AU  - Takes RP
AD  - Radboud University Medical Center, Department of Otorhinolaryngology and Head and 
      Neck Surgery, Nijmegen, the Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20231128
PL  - England
TA  - Eur J Surg Oncol
JT  - European journal of surgical oncology : the journal of the European Society of 
      Surgical Oncology and the British Association of Surgical Oncology
JID - 8504356
SB  - IM
MH  - Humans
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - *Laryngeal Neoplasms/diagnosis/surgery
MH  - Prognosis
MH  - *Carcinoma, Squamous Cell/diagnosis/therapy
MH  - Follow-Up Studies
MH  - Retrospective Studies
MH  - Neoplasm Recurrence, Local/diagnosis
MH  - *Head and Neck Neoplasms
OTO - NOTNLM
OT  - Head and neck cancer
OT  - Laryngeal cancer
OT  - Recurrence
OT  - Routine follow-up
OT  - Surveillance
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/12/04 00:42
MHDA- 2024/01/16 06:41
CRDT- 2023/12/03 18:10
PHST- 2023/07/25 00:00 [received]
PHST- 2023/10/30 00:00 [revised]
PHST- 2023/11/24 00:00 [accepted]
PHST- 2024/01/16 06:41 [medline]
PHST- 2023/12/04 00:42 [pubmed]
PHST- 2023/12/03 18:10 [entrez]
AID - S0748-7983(23)00942-3 [pii]
AID - 10.1016/j.ejso.2023.107304 [doi]
PST - ppublish
SO  - Eur J Surg Oncol. 2024 Jan;50(1):107304. doi: 10.1016/j.ejso.2023.107304. Epub 
      2023 Nov 28.